Literature DB >> 34671894

5-Oxo-hexahydroquinoline and 5-oxo-tetrahydrocyclopentapyridine derivatives as promising antiproliferative agents with potential apoptosis-inducing capacity.

Sara Ranjbar1,2, Mehdi Khoshneviszadeh2,3, Marjan Tavakkoli2, Ramin Miri2, Najmeh Edraki4, Omidreza Firuzi5.   

Abstract

Discovery of novel anticancer agents is of crucial importance to expand the therapeutic options for cancer patients. In this study, a series of 49 5-oxo-hexahydroquinoline and 5-oxo-tetrahydrocyclopentapyridine analogs, containing different pyridine alkyl carboxylates at C3 and various aliphatic, aromatic, and heteroaromatic substitutions at the C4 position of the central core, were synthesized. The target compounds were tested for antiproliferative effect against three human cancer cell lines including MOLT-4 (acute lymphoblastic leukemia), K562 (chronic myelogenous leukemia), and MCF-7 (breast adenocarcinoma) by MTT assay, and the effect of the most potent derivatives on cell cycle was evaluated by RNase/propidium iodide (PI) flow cytometric assay. Generally, 5-oxo-hexahydroquinoline derivatives (E series) possessed superior antiproliferative activities compared to their 5-oxo-tetrahydrocyclopentapyridine counterparts (F series). 5-Oxo-hexahydroquinoline compounds bearing 2-pyridyl propyl carboxylate (group D) and 3-pyridyl propyl carboxylate (group E) were better antiproliferative agents than those bearing other pyridyl alkyl carboxylates. Five best compounds with IC50 values in the range of 9.5-22.9 µM against MOLT-4 cells were selected for cell-cycle analysis, which revealed that derivatives D5, E3, and E5 with 2,3-dichlorophenyl, 3-nitrophenyl, and 2-nitrophenyl substitutions at C4 position, respectively, may induce apoptosis in MOLT-4 cells. Molecular docking analysis, which was employed to make some predictions on the interaction of the most active derivatives with the binding site of Bcl-2 and Bcl-xL proteins, suggested that the compounds may be well accommodated within the binding sites of these anti-apoptotic proteins via hydrogen-bonding and hydrophobic interactions. The findings of this study present 5-oxo-hexahydroquinoline derivatives as antiproliferative agents with potential apoptosis-inducing ability in cancer cells.
© 2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Entities:  

Keywords:  Anticancer activity; Bcl-2; Cytotoxicity; Dihydropyridine; Drug design; Hematological malignancies; Quinoline

Mesh:

Substances:

Year:  2021        PMID: 34671894     DOI: 10.1007/s11030-021-10281-9

Source DB:  PubMed          Journal:  Mol Divers        ISSN: 1381-1991            Impact factor:   2.943


  29 in total

1.  5-Oxo-hexahydroquinoline derivatives as modulators of P-gp, MRP1 and BCRP transporters to overcome multidrug resistance in cancer cells.

Authors:  Sara Ranjbar; Ruttiros Khonkarn; Alexis Moreno; Hélène Baubichon-Cortay; Ramin Miri; Mehdi Khoshneviszadeh; Luciano Saso; Najmeh Edraki; Pierre Falson; Omidreza Firuzi
Journal:  Toxicol Appl Pharmacol       Date:  2018-11-02       Impact factor: 4.219

Review 2.  The assessment and management of chemotherapy-related toxicities in patients with breast cancer, colorectal cancer, and Hodgkin's and non-Hodgkin's lymphomas: A scoping review.

Authors:  Patricia Fox; Andrew Darley; Eileen Furlong; Christine Miaskowski; Elisabeth Patiraki; Jo Armes; Emma Ream; Constantina Papadopoulou; Lisa McCann; Nora Kearney; Roma Maguire
Journal:  Eur J Oncol Nurs       Date:  2016-12-22       Impact factor: 2.398

3.  Novel structure-activity relationships and selectivity profiling of cage dimeric 1,4-dihydropyridines as multidrug resistance (MDR) modulators.

Authors:  Claudius Coburger; Jörg Wollmann; Martin Krug; Christiane Baumert; Marianne Seifert; Joséf Molnár; Hermann Lage; Andreas Hilgeroth
Journal:  Bioorg Med Chem       Date:  2010-06-09       Impact factor: 3.641

Review 4.  Chemotherapeutic Agents and the Risk of Ischemia and Arterial Thrombosis.

Authors:  Saamir A Hassan; Nicolas Palaskas; Peter Kim; Cezar Iliescu; Juan Lopez-Mattei; Elie Mouhayar; Rohit Mougdil; Kara Thompson; Jose Banchs; Syed Wamique Yusuf
Journal:  Curr Atheroscler Rep       Date:  2018-02-08       Impact factor: 5.113

5.  3,5-dibenzoyl-1,4-dihydropyridines: synthesis and MDR reversal in tumor cells.

Authors:  Masami Kawase; Anamik Shah; Harsukh Gaveriya; Noboru Motohashi; Hiroshi Sakagami; Andreas Varga; Joseph Molnár
Journal:  Bioorg Med Chem       Date:  2002-04       Impact factor: 3.641

6.  Cancer treatment and survivorship statistics, 2016.

Authors:  Kimberly D Miller; Rebecca L Siegel; Chun Chieh Lin; Angela B Mariotto; Joan L Kramer; Julia H Rowland; Kevin D Stein; Rick Alteri; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2016-06-02       Impact factor: 508.702

7.  Synthesis and biological evaluation of some new 1,4-dihydropyridines containing different ester substitute and diethyl carbamoyl group as anti-tubercular agents.

Authors:  Mehdi Khoshneviszadeh; Najmeh Edraki; Katayoun Javidnia; Abdolvahab Alborzi; Bahman Pourabbas; Jalal Mardaneh; Ramin Miri
Journal:  Bioorg Med Chem       Date:  2009-01-06       Impact factor: 3.641

8.  Novel 5-oxo-hexahydroquinoline derivatives: design, synthesis, in vitro P-glycoprotein-mediated multidrug resistance reversal profile and molecular dynamics simulation study.

Authors:  Omolbanin Shahraki; Najmeh Edraki; Mehdi Khoshneviszadeh; Farshid Zargari; Sara Ranjbar; Luciano Saso; Omidreza Firuzi; Ramin Miri
Journal:  Drug Des Devel Ther       Date:  2017-02-14       Impact factor: 4.162

9.  Editorial: Adverse Effects of Cancer Chemotherapy: Anything New to Improve Tolerance and Reduce Sequelae?

Authors:  Kulmira Nurgali; R Thomas Jagoe; Raquel Abalo
Journal:  Front Pharmacol       Date:  2018-03-22       Impact factor: 5.810

10.  Tetrahydroquinolinone derivatives as potent P-glycoprotein inhibitors: design, synthesis, biological evaluation and molecular docking analysis.

Authors:  S Ranjbar; O Firuzi; N Edraki; O Shahraki; L Saso; M Khoshneviszadeh; R Miri
Journal:  Medchemcomm       Date:  2017-08-23       Impact factor: 3.597

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.